Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

Study Overview
=================
Brief Summary
-----------------
The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Detailed Description
-----------------
The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt. Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.

Official Title
-----------------
Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection

Conditions
-----------------
Thyroid Cancer

Intervention / Treatment
-----------------
* Drug: Iodine-124
* Drug: Iodine-123
* Drug: F-18 FDG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:- Patient at Nuclear Medicine clinic at Stanford University Medical Center Treated thyroid cancer. Detectable levels of Tg. Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer. Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT Patients older than 18-year-old. Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg. Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT. Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them. Exclusion Criteria:- Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT. Patients who cannot complete I-123 WBS and F-18 FDG PET/CT. Pregnant women. Healthy volunteers. Patients participating in other research studies.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Iodine-124|2 mCi, oral|
|Drug: Iodine-123|2 mCi, oral|
|Drug: F-18 FDG|10-15 mCi, iv|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |